ESBATech is drug discovery company, exploiting its expertise in yeast technology for the development of therapeutic antibody fragments and the development of functional assays for small molecule screenings More
The discovery by Kohler and Milstein in 1975 that it was possible to generate monoclonal antibodies via hybridoma technology sparked a scientific revolution - and the consequences have been awesome More
The 'Harvard Oncomouse' patent claimed a method for producing transgenic non-human mammals with a predisposition to developing cancer. The prospect of the commercialisation of animals fated to develop cancer was the cause of significant protest. More
The potential of the post genomic era has not yet translated into new levels of drug discovery. This talk will explore various hypotheses to explain the conundrum. More
In the past thirty years the prevalence of allergicdisorders, especially asthma, has risen steadily in the world. This paper covers new immunotherapy approaches using immunoglobin as the target. More
All rights reserved. Terms and Conditions | Contact us
